Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?
- 1 June 2011
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 35 (6) , e84-e86
Abstract
No abstract availableKeywords
Funding Information
- Sundhed og Sygdom, Det Frie Forskningsråd
- Novo Nordisk Fonden
- Kræftens Bekæmpelse (R2-A198-09-S2)
This publication has 8 references indexed in Scilit:
- Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 studyBlood, 2010
- Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicinBlood, 2008
- Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) projectLeukemia Research, 2007
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrenceCancer, 2005
- Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemiaBlood, 2005
- Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemiaAnti-Cancer Drugs, 2002
- Mylotarg: antibody-targeted chemotherapy comes of ageCurrent Opinion in Oncology, 2001
- Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapseExpert Opinion on Biological Therapy, 2001